| Literature DB >> 33927978 |
Sha Li1, Chen Wang1, Yifang Lu1, Weijuan Li1.
Abstract
The long non-coding RNA (lncRNA) LIFR-AS1 has been shown to be involved in the development of several human cancers. This study was designed to determine the expression profile and role of lncRNA-LIFR-AS1 in human thyroid cancer. The results showed significant (p < 0.05) upregulation of LncRNA-LIFR-AS1 in thyroid cancer tissues and cells. However, silencing of LncRNA-LIFR-AS1 inhibited the viability and proliferation of human thyroid cancer cells inducing G2/M cell cycle arrest. The G2/M phase cells increased from 8.56% in negative control (NC) to around 35.03% in si-LIFR-AS1. This was also found to be concomitant with the downregulation of cyclin B1 and CDK1 expressions. The thyroid cancer cells exhibited remarkably lower invasion and migration under transcriptional knockdown of lncRNA-LIFR-AS1 which was also associated with downregulation of MMP-2 and MMP-9 expression. Importantly, transcriptional silencing of lncRNA-LIFR-AS1 inhibited thyroid cancer tumorigenesis, in vivo. Collectively, the results suggest the tumor-promoting role of lncRNA-LIFR-AS1 in thyroid cancer and highlight its potential as therapeutic target. © King Abdulaziz City for Science and Technology 2021.Entities:
Keywords: Cell cycle arrest; LncRNA-LIFR-AS1; Long non-coding RNAs; Thyroid cancer; Xenograft
Year: 2021 PMID： 33927978 PMCID： PMC7985231 DOI： 10.1007/s13205-021-02739-2
Source DB: PubMed Journal: 3 Biotech ISSN： 2190-5738 Impact factor: 2.406